An observational study in Cardiovascular Diseases, Atherosclerotic Cardiovascular Disease and Hypercholesterolemia, Familial, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.
5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.
This study's planned enrollment of 5,995 is above the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients in Italy who initiated inclisiran, evolocumab, or alirocumab treatment during the identification period with at least 18 months of follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Patients receiving inclisiran injection(s).
Patients receiving evolocumab injection(s).
Patients receiving alirocumab injection(s).
Patients receiving anti-PCSK9-mAbs either evolocumab or alirocumab.
Proportion of Days Covered (PDC) With Inclisiran
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest. Index date is the date of first use of the treatment.
Time frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
Annual PDC With Inclisiran
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest.
Time frame: 0-12 months, 12-24 months, 24-48 months
Persistence With Inclisiran Treatment
Persistence is defined as time to discontinuation by exceeding a pre-specified allowable gap beyond the scheduled time for the next dose/prescription. Index date is the date of first use of the treatment.
Time frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
PDC With Anti-PCSK9-mAbs
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest. Index date is the date of first use of the treatment.
Time frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
Annual PDC With Anti-PCSK9-mAbs
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest.
Time frame: 0-12 months, 12-24 months, 24-48 months
Persistence With Anti-PCSK9-mAb Treatment
Persistence is defined as time to discontinuation by exceeding a pre-specified allowable gap beyond the scheduled time for the next dose/prescription. Index date is the date of first use of the treatment.
Time frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
Baseline Demographics
Time frame: Baseline
Baseline Clinical Characteristics: Number of Patients by Diagnosis
Diagnoses include primary hypercholesterolemia, mixed dyslipidemia, homozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease (ASCVD) where available.
Time frame: Baseline
Baseline Clinical Characteristics: Number of Patients by Comorbidity
Time frame: Baseline
Baseline Clinical Characteristics: Charlson Comorbidity Index (CCI) Score
CCI is a weighted index that takes into account both the number and the seriousness of comorbid diseases. It predicts the ten-year mortality for a patient who may have a range of comorbid conditions. CCI can be categorized as low (0-1) and high (≥2).
Time frame: Baseline
PDC With Lipid Lowering Therapies (LLTs) at Baseline
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest.
Time frame: Baseline
Number of Patients by LLTs Received
Treatment patterns of LLT use. Index date is the date of first use of the treatment.
Time frame: Every 3 months from baseline through index date until the end of follow-up, assessed up to 48 months
Number and Percentage of Patients Receiving Each of the Inclisiran Doses
Index date is the date of first use of the treatment.
Time frame: From index date until the end of follow-up, assessed up to 48 months
Time Between Inclisiran Doses
Index date is the date of first use of the treatment.
Time frame: From index date until the end of follow-up, assessed up to 48 months
Number of Anti-PCSK9-mAb Prescriptions
Index date is the date of first use of the treatment.
Time frame: From index date until the end of follow-up, assessed up to 48 months
Time Between Anti-PCSK9-mAb Prescriptions
Index date is the date of first use of the treatment.
Time frame: From index date until the end of follow-up, assessed up to 48 months
Association Between Treatment Adherence and Baseline Characteristics per Cohort
Multivariable regression models will be used to examine how baseline characteristics could be associated with treatment adherence per cohort. Baseline characteristics may include age, sex, diagnosis, cardiovascular events, comorbidities, adherence to LLTs, and number of medications received at index and post-index.
Time frame: Baseline, up to 48 months
Association Between Treatment Persistence and Baseline Characteristics per Cohort
Cox proportional hazards models will be used to examine how baseline characteristics could be associated with treatment persistence per cohort. Baseline characteristics may include age, sex, diagnosis, cardiovascular events, comorbidities, adherence to LLTs, and number of medications received at index and post-index.
Time frame: Baseline, up to 48 months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.